DAWN
NEUTRAL
$21.46
Live
Day One Biopharmaceuticals, Inc. · NASDAQ
Target $21.5
(+0.2%)
$5.63
52W Range
$21.47
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$2.22B
P/E
N/A
ROE
-22.7%
Profit margin
-67.8%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
DAWN shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong revenue growth of 83.9%
Low debt with D/E ratio of 0.01
Key Risks
Low profit margin of -67.8%
Weak financial trend (Piotroski F-Score: 1/9)
Weak ROE of -22.7%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
50
65
30
35
0
AI Verdict
DAWN shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong revenue growth of 83.9%, Low debt with D/E ratio of 0.01, Low profit margin of -67.8%
Confidence
40%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 83.9%.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -8.7% over 5Y and +205.7% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -22.7%.
- Thin profit margins.
Health
35/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.01).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$21.46
Analyst Target
$21.5
Upside/Downside
+0.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DAWN and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
Primary
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
ACHC
Acadia Healthcare Company, Inc.
Peer
|
-61.4% | -66.0% | -16.5% | +8.2% | +51.5% | -8.2% |
|
AHG
Akso Health Group
Peer
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
DAW
Day One Biopharmaceuticals, Inc.
Primary
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
ACH
Acadia Healthcare Company, Inc.
Peer
5Y
-61.4%
3Y
-66.0%
1Y
-16.5%
6M
+8.2%
1M
+51.5%
1W
-8.2%
AHG
Akso Health Group
Peer
5Y
+24.4%
3Y
+547.7%
1Y
+88.2%
6M
+30.8%
1M
+77.3%
1W
+85.2%
ATE
Alphatec Holdings, Inc.
Peer
5Y
+4.7%
3Y
+20.4%
1Y
+33.9%
6M
+44.4%
1M
-24.8%
1W
-11.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-502.46
PEG Ratio
N/A
P/B Ratio
5.01
P/S Ratio
14.01
EV/Revenue
11.24
EV/EBITDA
-14.31
Market Cap
$2.22B
Profitability
Profit margins and return metrics
Profit Margin
-67.85%
Operating Margin
-51.12%
Gross Margin
89.12%
ROE
-22.74%
ROA
-14.64%
Growth
Revenue and earnings growth rates
Revenue Growth
+83.9%
Earnings Growth
N/A
Q/Q Revenue Growth
+83.92%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
8.02
Strong
Quick Ratio
7.73
Excellent
Cash/Share
$4.27
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
88.7%
Op. Margin
-51.1%
Net Margin
-39.6%
Total Assets
$0.5B
Liabilities
$0.1B
Equity
$0.4B
Debt/Equity
0.15x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$-0.21
-38.9% surprise
2025-11-04
$-0.19
+32.4% surprise
2025-08-05
$-0.29
+15.5% surprise
Healthcare Sector Comparison
Comparing DAWN against 174 companies in the Healthcare sector
(15 bullish, 57 neutral, 102 bearish)
Return on Equity (ROE)
-22.74%
This Stock
vs
-44.63%
Sector Avg
-49.0%
(Below Avg)
Profit Margin
-67.85%
This Stock
vs
-21.27%
Sector Avg
+219.0%
(Superior)
Debt to Equity
0.01
This Stock
vs
5.38
Sector Avg
-99.9%
(Less Debt)
Revenue Growth
83.9%
This Stock
vs
114.69%
Sector Avg
-26.8%
(Slower)
Current Ratio
8.02
This Stock
vs
3.43
Sector Avg
+133.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $2.17B | - | -41.0% | -33.3% | $23.52 | Compare |
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | Compare |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
DAWN
Day One...
NEUTRAL
Mkt Cap
$2.2B
P/E
-
ROE
-22.7%
Price
$21.46
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-17 | YORK CHARLES N. II CPA | Chief Operating Officer | Sale | 6,065 | $70,359 |
| 2026-02-17 | VASCONCELLES MICHAEL | Officer | Sale | 2,728 | $31,647 |
| 2026-02-17 | DUBOW ADAM | General Counsel | Sale | 6,395 | $74,188 |
| 2026-02-17 | MERENDINO LAUREN | Officer | Sale | 5,814 | $67,448 |
| 2026-02-17 | BENDER JEREMY | Chief Executive Officer | Sale | 15,459 | $179,338 |
| 2026-02-13 | YORK CHARLES N. II CPA | Chief Operating Officer | Stock Award | 23,375 | - |
| 2026-02-13 | VASCONCELLES MICHAEL | Officer | Stock Award | 7,125 | - |
| 2026-02-13 | DUBOW ADAM | General Counsel | Stock Award | 16,463 | - |
| 2026-02-13 | MERENDINO LAUREN | Officer | Stock Award | 15,162 | - |
| 2026-02-13 | BENDER JEREMY | Chief Executive Officer | Stock Award | 42,937 | - |
| 2025-11-25 | BENDER JEREMY | Chief Executive Officer | Gift | 614,450 | - |
| 2025-11-17 | YORK CHARLES N. II CPA | Chief Operating Officer | Sale | 4,062 | $36,212 |
| 2025-11-17 | DUBOW ADAM | General Counsel | Sale | 4,319 | $38,503 |
| 2025-11-17 | MERENDINO LAUREN | Officer | Sale | 3,726 | $33,216 |
| 2025-11-17 | BENDER JEREMY | Chief Executive Officer | Sale | 15,894 | $141,690 |
YORK CHARLES N. II CPA
Chief Operating Officer
2026-02-17
6,065 shares
·
$70,359
VASCONCELLES MICHAEL
Officer
2026-02-17
2,728 shares
·
$31,647
DUBOW ADAM
General Counsel
2026-02-17
6,395 shares
·
$74,188
MERENDINO LAUREN
Officer
2026-02-17
5,814 shares
·
$67,448
BENDER JEREMY
Chief Executive Officer
2026-02-17
15,459 shares
·
$179,338
YORK CHARLES N. II CPA
Chief Operating Officer
2026-02-13
23,375 shares
VASCONCELLES MICHAEL
Officer
2026-02-13
7,125 shares
DUBOW ADAM
General Counsel
2026-02-13
16,463 shares
MERENDINO LAUREN
Officer
2026-02-13
15,162 shares
BENDER JEREMY
Chief Executive Officer
2026-02-13
42,937 shares
BENDER JEREMY
Chief Executive Officer
2025-11-25
614,450 shares
YORK CHARLES N. II CPA
Chief Operating Officer
2025-11-17
4,062 shares
·
$36,212
DUBOW ADAM
General Counsel
2025-11-17
4,319 shares
·
$38,503
MERENDINO LAUREN
Officer
2025-11-17
3,726 shares
·
$33,216
BENDER JEREMY
Chief Executive Officer
2025-11-17
15,894 shares
·
$141,690
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
6 analysts
JP Morgan
2026-03-11
Overweight
Neutral
HC Wainwright & Co.
2026-03-10
Buy
Neutral
Wedbush
2026-03-09
Outperform
Neutral
Jones Trading
2026-03-06
Buy
Hold
Needham
2026-03-06
Buy
Hold
Wedbush
2026-02-25
Outperform
Outperform
HC Wainwright & Co.
2026-02-25
Buy
Buy
Needham
2026-02-25
Buy
Buy
TD Cowen
2026-01-13
Buy
HC Wainwright & Co.
2025-11-24
Buy
Buy
Past News Coverage
Recent headlines mentioning DAWN from our newsroom.
Newest → oldest
No matching news yet.